Cancer Causes & Control

, Volume 25, Issue 8, pp 985–997

Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening

  • Dolores Salas
  • Mercedes Vanaclocha
  • Josefa Ibáñez
  • Ana Molina-Barceló
  • Vicente Hernández
  • Joaquín Cubiella
  • Raquel Zubizarreta
  • Montserrat Andreu
  • Cristina Hernández
  • Francisco Pérez-Riquelme
  • José Cruzado
  • Fernando Carballo
  • Luis Bujanda
  • Cristina Sarasqueta
  • Isabel Portillo
  • Mariola de la Vega-Prieto
  • Juan Diego Morillas
  • Vicente Valentín
  • Ángel Lanas
  • Enrique Quintero
  • Antoni Castells
Original paper

Abstract

Purpose

To compare two strategies for colorectal cancer screening: one-time colonoscopy versus fecal immunochemical testing (FIT) (and colonoscopy for positive) every 2 years, in order to determine which strategy provides the highest participation and detection rates in groups of sex and age.

Methods

This analysis was performed with data from the first screening round within the COLONPREV study, a population-based, multicenter, nationwide trial carried out in Spain. Several logistic regression models were applied to identify the influence of the screening test on participation rates and detection of proximal and distal neoplasms, as well to identify the influence of age and sex: women aged 50–59 years, women aged 60–69 years, men aged 50–59 years, and men aged 60–69 years.

Results

Participation was higher in women than in men, especially among women aged 50–59 years (25.91 % for colonoscopy and 35.81 % for FIT). Crossover from colonoscopy to FIT was higher among women than men, especially among those aged 60–69 years (30.37 %). In general, detection of any neoplasm and advanced adenoma was higher with colonoscopy than with FIT, but no significant differences were found between the two strategies for colorectal cancer detection. Detection of advanced adenoma in both arms was lower in women [specifically in women aged 50–59 years (OR 0.31; 95 % CI 0.25–0.38) than in men aged 60–69 years]. Women aged 50–59 years in the colonoscopy arm had a higher probability of detection of advanced adenoma (OR 4.49; 95 % CI 3.18–6.35), as well as of detection of neoplasms in proximal and distal locations (proximal OR 19.34; 95 % CI 12.07–31.00; distal OR 11.04; 95 % CI 8.13–15.01) than women of the same age in the FIT arm. These differences were also observed in the remaining groups but to a lesser extent.

Conclusion

Women were more likely to participate in a FIT-based strategy, especially those aged 50–59 years. The likelihood of detection of any neoplasm was higher in the colonoscopy arm for all the population groups studied, especially in women aged 50–59 years. Distinct population groups should be informed of the benefits of each screening strategy so that they may take informed decisions.

Keywords

Cancer colorectal screening Fecal immunochemical testing Colonoscopy Gender Age 

References

  1. 1.
    Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ, American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570–1595Google Scholar
  2. 2.
    Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343(22):1603–1607PubMedCrossRefGoogle Scholar
  3. 3.
    Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103(6):1541–1549PubMedCrossRefGoogle Scholar
  4. 4.
    Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J, UK Flexible Sigmoidoscopy Trial Investigators (2010) Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726):1624–1633PubMedCrossRefGoogle Scholar
  5. 5.
    Parkin DM, Tappenden P, Olsen AH, Patnick J, Sasieni P (2008) Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen 15(4):163–174PubMedCrossRefGoogle Scholar
  6. 6.
    von Wagner C, Good A, Wright D, Rachet B, Obichere A, Bloom S, Wardle J (2009) Inequalities in colorectal cancer screening participation in the first round of the national screening programme in England. Br J Cancer 3(101 Suppl 2):S60–S63CrossRefGoogle Scholar
  7. 7.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCANGoogle Scholar
  8. 8.
    Brasso K, Lynge E (2010) Determinants of participation in colorectal cancer screening with faecal occult blood testing. J Public Health (Oxf) 32(3):395–405CrossRefGoogle Scholar
  9. 9.
    Wardle J, Miles A, Atkin W (2005) Gender differences in utilization of colorectal cancer screening. J Med Screen 12(1):20–27PubMedCrossRefGoogle Scholar
  10. 10.
    Javanparast S, Ward P, Young G, Wilson C, Carter S, Misan G, Cole S, Jiwa M, Tsourtos G, Martini A, Gill T, Baratiny G, Matt MA (2010) How equitable are colorectal cancer screening programs which include FOBTs? A review of qualitative and quantitative studies. Prev Med 50(4):165–172PubMedCrossRefGoogle Scholar
  11. 11.
    Hassan C, Giorgi Rossi P, Camilloni L, Rex DK, Jimenez-Cendales B, Ferroni E, Borgia P, Zullo A, Guasticchi G, HTA Group (2012) Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther 36(10):929–940PubMedCrossRefGoogle Scholar
  12. 12.
    Hol L, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, van Dekken H, Reijerink JC, van der Togt AC, Habbema JD, Kuipers EJ (2010) Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59(1):62–68PubMedCrossRefGoogle Scholar
  13. 13.
    Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M, SCORE3 Working Group-Italy (2007) Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 132(7):2304–2312PubMedCrossRefGoogle Scholar
  14. 14.
    Lieberman D (2009) Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 25(5):422–427PubMedCrossRefGoogle Scholar
  15. 15.
    Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT (2013) Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369(12):1095–1105PubMedCrossRefGoogle Scholar
  16. 16.
    Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A, COLONPREV Study Investigators (2012) Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 366(8):697–706PubMedCrossRefGoogle Scholar
  17. 17.
    Jover R, Herráiz M, Alarcón O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreño R, Castells A, Cubiella J, García-Iglesias P, Hervás AJ, Menchén P, Ono A, Panadés A, Parra-Blanco A, Pellisé M, Ponce M, Quintero E, Reñé JM, Sánchez del Río A, Seoane A, Serradesanferm A, Soriano Izquierdo A, Vázquez Sequeiros E, Spanish Society of Gastroenterology, Spanish Society of Gastrointestinal Endoscopy Working Group (2012) Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44(4):444–451PubMedCrossRefGoogle Scholar
  18. 18.
    Pox CP, Altenhofen L, Brenner H, Theilmeier A, Von Stillfried D, Schmiegel W (2012) Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 142(7):1460–1467PubMedCrossRefGoogle Scholar
  19. 19.
    Wong MC, John GK, Hirai HW, Lam TY, Luk AK, Ching JY, Ng SS, Chan FK, Griffiths SM, Sung JJ (2012) Changes in the choice of colorectal cancer screening tests in primary care settings from 7,845 prospectively collected surveys. Cancer Causes Control 23(9):1541–1548PubMedCrossRefGoogle Scholar
  20. 20.
    Senore C, Ederle A, Benazzato L, Arrigoni A, Silvani M, Fantin A, Fracchia M, Armaroli P, Segnan N (2013) Offering people a choice for colorectal cancer screening. Gut 62(5):735–740PubMedCrossRefGoogle Scholar
  21. 21.
    Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR (2009) Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 7(12):1272–1278PubMedCrossRefGoogle Scholar
  22. 22.
    Lieberman DA, Weiss DG, Harford WV, Ahnen DJ, Provenzale D, Sontag SJ, Schnell TG, Chejfec G, Campbell DR, Kidao J, Bond JH, Nelson DB, Triadafilopoulos G, Ramirez FC, Collins JF, Johnston TK, McQuaid KR, Garewal H, Sampliner RE, Esquivel R, Robertson D (2007) Five-year colon surveillance after screening colonoscopy. Gastroenterology 133(4):1077–1085PubMedCrossRefGoogle Scholar
  23. 23.
    Imperiale TF, Glowinski EA, Lin-Cooper C, Ransohoff DF (2012) Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. Am J Med 125(12):1181–1187PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Crotta S, Segnan N, Paganin S, Dagnes B, Rosset R, Senore C (2012) High rate of advanced adenoma detection in 4 rounds of colorectal cancer screening with the fecal immunochemical test. Clin Gastroenterol Hepatol 10(6):633–638PubMedCrossRefGoogle Scholar
  25. 25.
    European guidelines for quality assurance in colorectal cancer screening and diagnosis (2011). Brussels: European Commission. IOP Publishing Physics Web. http://bookshop.europa.eu/is-bin/INTERSHOP.enfinity/WFS/EU-Bookshop-Site/en_GB/-/EUR/ViewPublication-Start?PublicationKey=ND3210390. Accessed 14 Jan 2014

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Dolores Salas
    • 1
    • 2
  • Mercedes Vanaclocha
    • 2
  • Josefa Ibáñez
    • 1
    • 2
  • Ana Molina-Barceló
    • 2
  • Vicente Hernández
    • 3
  • Joaquín Cubiella
    • 4
  • Raquel Zubizarreta
    • 5
  • Montserrat Andreu
    • 6
  • Cristina Hernández
    • 7
  • Francisco Pérez-Riquelme
    • 8
    • 9
  • José Cruzado
    • 8
    • 9
  • Fernando Carballo
    • 9
    • 10
  • Luis Bujanda
    • 11
  • Cristina Sarasqueta
    • 12
  • Isabel Portillo
    • 13
  • Mariola de la Vega-Prieto
    • 14
  • Juan Diego Morillas
    • 15
  • Vicente Valentín
    • 16
  • Ángel Lanas
    • 17
  • Enrique Quintero
    • 18
  • Antoni Castells
    • 19
  1. 1.General Directorate Public HealthValenciaSpain
  2. 2.Centre for Public Health Research (CSISP)FISABIOValenciaSpain
  3. 3.Department of GastroenterologyComplexo Hospitalario Universitario de VigoVigoSpain
  4. 4.Department of GastroenterologyComplexo Hospitalario Universitario de OurenseOurenseSpain
  5. 5.Directorate for Innovation and Management of Public HealthSantiago de CompostelaSpain
  6. 6.Department of Gastroenterology, Hospital del Mar, Hospital del Mar Medical Research Institute (IMIM)Pompeu Fabra UniversityBarcelona, CataloniaSpain
  7. 7.Department of Epidemiology and Evaluation, Hospital del MarHospital del Mar Medical Research Institute (IMIM)Barcelona, CataloniaSpain
  8. 8.General Directorate Public HealthMurciaSpain
  9. 9.Institute of Bio-health Research of Murcia (IMIB)MurciaSpain
  10. 10.Department of GastroenterologyVirgen de la Arrixaca Universitary HospitalMurciaSpain
  11. 11.Department of Gastroenterology, Donostia Hospital-Instituto Biodonostia, CIBERehdUniversity of Basque Country (UPV/EHU)San SebastiánSpain
  12. 12.Donostia Hospital-Instituto BiodonostiaREDISSECSan SebastiánSpain
  13. 13.Basque Health ServiceBasque CountrySpain
  14. 14.General Directorate of Health Care ProgrammesCanary Islands Health ServiceSanta CruzSpain
  15. 15.Department of Gastroenterology12 de Octubre HospitalMadridSpain
  16. 16.Regional Office for Oncology CoordinationConsejería de SanidadMadridSpain
  17. 17.Department of Gastroenterology, IIS Aragón, CIBERehdUniversity of ZaragozaZaragozaSpain
  18. 18.Department of GastroenterologyCanarias Universitary HospitalTenerifeSpain
  19. 19.Department of Gastroenterology, Hospital Clínic, CIBERehdInstitut d’Investigacions Biomediques August Pi i SunyerBarcelonaSpain

Personalised recommendations